Abstract: The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.

Abstract: The present invention relates to an injenane-type diterpene compound derived from Euphorbia kansui Liou, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the injenane-type diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hepatitis C virus (HCV) infectious disease. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating HCV infectious disease or an antiviral composition for HCV, containing at least one selected from the group consisting of: GRIM19 protein or a fragment thereof; and a gene encoding the protein or a fragment of the protein.

Abstract: The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Abstract: The present invention relates to a composition including neural cells and an elastin-like polypeptide for treating Parkinson's diseases. More particularly, the present invention relates to a composition for treating Parkinson's diseases, which can more effectively increase a survival rate and settling rate of neural cells transplanted to an acutely or chronically damaged nerve region for treatment of Parkinson's disease, by simultaneously administering an elastin-like polypeptide with neural cells.

Abstract: A method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

Abstract: The present invention relates to an antiviral composition containing an Aleurites fordii or Daphne kiusiana extract or a fraction thereof as an active ingredient. In detail, extracts of Aleurites fordii or Daphne kiusiana or fractions thereof can induce the secretion of an immune-related cytokine, interferon-? (IFN-?) in natural killer (NK) cells, and thus exhibit potent antiviral activity and superior effects for viral diseases, and therefore can be effectively used in an antiviral composition.

Abstract: A display device includes a display panel having a display area and a bezel area formed around edges of the display area; a backlight unit disposed on a rear side of the display panel to provide light to the display panel; a supporting member to support the display panel and the backlight unit; and a top case having at least one joint and incorporated with a surface of the supporting member, wherein the top case has a main frame combined with the supporting member, and a sub frame having a design of at least one color and disposed on the bezel area.

Abstract: A display device includes a display panel having a display area and a bezel area formed around edges of the display area; a backlight unit disposed on a rear side of the display panel to provide light to the display panel; a supporting member to support the display panel and the backlight unit; and a top case having at least one joint and incorporated with a surface of the supporting member, wherein the top case has a main frame combined with the supporting member and a sub frame disposed on the bezel area and combined with the main frame.

Abstract: An optical touch display device which is advantageous in high-speed driving, large-area touch sensing, and multi-touch sensing because of use of an image map and which can improve touch sensing performance and a driving method thereof are provided. The optical touch display device includes a display device configured to display a display image based on input source image data and an image map for touch sensing, an optical touch pen configured to detect map information of the image map displayed on the display device, and a position detector configured to detect position information (coordinate information) on a screen based on the map information.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of Styrax japonica, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-?1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.

Abstract: An apparatus and method of segmenting sensor data are provided. The apparatus includes a sensor, a first segmentation unit, a continuity evaluation unit, a second segmentation unit, and a segmentation determination unit. The sensor collects sensor data for a process of the semiconductor manufacturing facility. The first segmentation unit extracts a variation point of the sensor data to perform an abnormal difference (AD) segmentation on the sensor data based on the at least one variation point. The continuity evaluation unit evaluates a continuity ratio of the sensor data. The second segmentation unit performs a free-knot spline (FS) segmentation on the sensor data when the continuity ratio exceeds a reference ratio. The segmentation determination unit compares the AD segmentation result with the PS segmentation result and to select one of the results on the comparison result.

Abstract: The present invention relates to an injenane-type diterpene compound derived from Euphorbia kansui Liou, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the injenane-type diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.

Abstract: Provided is a display device including, a substrate, a display pan& disposed on the substrate, a sealing substrate disposed over the display panel, a sealing part disposed between the substrate and the sealing substrate to at least partially surround the display panel, and a buffer part proximate to a corner region of the sealing part to at least partially surround the corner region of the sealing part, the buffer part extending from the substrate to the sealing substrate.

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of asthma comprising Wogonin as an active ingredient. The Wogonin of the present invention is excellent not only in relieving airway hypersensitivity that causes asthma in vivo, in inhibiting reactive oxygen species generation in the airway, and in inhibiting the infiltration of inflammatory cells in the bronchus, but also in inhibiting the generation of IgE in serum and bronchoalveolar lavage fluid, and in inhibiting the expressions of Th2 cytokines in the lung. Therefore, the Wogonin of the present invention can be effectively used as a composition for the prevention, treatment, or improvement of asthma.

Abstract: Disclosed is a pharmaceutical composition for the prophylaxis and therapy of inflammatory diseases, allergic diseases, or asthma, comprising a velvet apple (Diospyros blancoi A. DC.) extract as an active ingredient. Having the inhibitory activity against the nuclear translocation of NF-?B, whose level is rapidly elevated in response to inflammatory stimuli, the velvet apple extract can suppress the production of NO and PGE2, the expression of iNOS and COX-2, and the release of IL-1? and TNF-?, and can significantly down regulate Th2-mediated IL-4 and IL-13 production. In addition, the extract was found to inhibit the activation of eosinophils in bronchoalveolar lavage fluid, and to suppress the secretion of immunoglobulins and chemokines in bronchoalveolar lavage fluid and blood, as measured by in vivo tests on an ovalbumin-induced asthma mouse model. Therefore, the extract can be used in the method for preventing or treating various inflammatory disorders, allergic diseases, or asthma.

Abstract: A display device includes a display panel having a display area and a bezel area formed around edges of the display area; a backlight unit disposed on a rear side of the display panel to provide light to the display panel; a supporting member to support the display panel and the backlight unit; and a top case having at least one joint and incorporated with a surface of the supporting member, wherein the top case has a main frame combined with the supporting member and a sub frame disposed on the bezel area and combined with the main frame.

Abstract: A display device includes a display panel having a display area and a bezel area formed around edges of the display area; a backlight unit disposed on a rear side of the display panel to provide light to the display panel; a supporting member to support the display panel and the backlight unit; and a top case having at least one joint and incorporated with a surface of the supporting member, wherein the top case has a main frame combined with the supporting member, and a sub frame having a design of at least one color and disposed on the bezel area.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of Styrax japonica, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-?1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.

Abstract: Disclosed is a pharmaceutical composition for the prophylaxis and therapy of inflammatory diseases, allergic diseases, or asthma, comprising a velvet apple (Diospyros blancoi A. DC.) extract as an active ingredient. Having the inhibitory activity against the nuclear translocation of NF-?B, whose level is rapidly elevated in response to inflammatory stimuli, the velvet apple extract can suppress the production of NO and PGE2, the expression of iNOS and COX-2, and the release of IL-1? and TNF-?, and can significantly down regulate Th2-mediated IL-4 and IL-13 production. In addition, the extract was found to inhibit the activation of eosinophils in bronchoalveolar lavage fluid, and to suppress the secretion of immunoglobulins and chemokines in bronchoalveolar lavage fluid and blood, as measured by in vivo tests on an ovalbumin-induced asthma mouse model. Therefore, the extract can be used in the method for preventing or treating various inflammatory disorders, allergic diseases, or asthma.